Medifast (MED) Reports Q4 Loss, Beats Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to earnings of $0.1 per share a year ago.
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Medifast's Q4 Earnings on Deck: What Could Shape MED's Results?
MED is likely to post a sharp Q4 revenue drop and a wider loss as active earning coaches decline and GLP-1 pressure weighs despite retention and pricing efforts.
Analysts Estimate Medifast (MED) to Report a Decline in Earnings: What to Look Out for
Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medifast Is A Net-Net With Negative Enterprise Value
Medifast trades below net cash, with an EV of -$43.68M, reflecting deep skepticism about its OPTAVIA MLM business and turnaround prospects. GLP-1 drugs have rendered MED's weight-loss model largely obsolete, prompting a pivot toward metabolic health services, though execution risk remains high. Despite ongoing losses, MED's cash burn is modest; even with conservative assumptions, shares likely remain a net-net with limited downside over the next year.
Medifast's Q4 Guidance Remains Weak: When Does Growth Return?
MED sees weak Q4 guidance after steep revenue declines, but a metabolic health pivot targets stabilization and recovery.
Medifast Shifts to Metabolic Health: A Durable Growth Path?
MED is pivoting to metabolic health, using clinical data and new products to address root causes beyond GLP-1 weight loss.
Medifast New Product Line Planned: Can Innovation Reignite Demand?
MED plans a new product line rooted in metabolic synchronization science, upgrading its core offerings as it shifts beyond weight loss.
Medifast's Third-Quarter Revenue Fell 36%: Is Stabilization Near?
MED witnesses revenue plunge as its coach base shrank, but restructuring and productivity initiatives aim to stabilize results by late 2025.
Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy?
MED targets long-term metabolic health with programs that preserve muscle and support lasting wellness amid GLP-1 adoption.
Medifast's Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y
MED's third-quarter results reflect pressure from fewer active OPTAVIA Coaches, but it is steering toward metabolic health for growth.
Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript
Medifast, Inc. ( MED ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Steven Zenker - Vice President of Investor Relations Daniel Chard - Executive Chairman & CEO James Maloney - Chief Financial Officer Nicholas Johnson - Chief Field Operations Officer Conference Call Participants James Salera - Stephens Inc., Research Division Presentation Operator Greetings, and welcome to the Medifast Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
